SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-307328
Filing Date
2022-12-16
Accepted
2022-12-16 16:07:57
Documents
13
Period of Report
2022-12-15
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d410964d8k.htm   iXBRL 8-K 32897
2 EX-3.1 d410964dex31.htm EX-3.1 165157
  Complete submission text file 0001193125-22-307328.txt   364352

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nrix-20221215.xsd EX-101.SCH 2851
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrix-20221215_lab.xml EX-101.LAB 18740
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrix-20221215_pre.xml EX-101.PRE 11708
7 EXTRACTED XBRL INSTANCE DOCUMENT d410964d8k_htm.xml XML 3563
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

IRS No.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: 8-K | Act: 34 | File No.: 001-39398 | Film No.: 221468036
SIC: 2834 Pharmaceutical Preparations